Literature DB >> 35273440

Prothymosin α Gene Transfer Modulates Myocardial Remodeling after Ischemia-Reperfusion Injury.

Ai-Li Shiau1,2, Shih-Yuan Fang3, Chih-Hsin Hsu4, Meng-Hsuan Chiu3, Chen-Fuh Lam5, Chao-Liang Wu2,6, Jun-Neng Roan7,8.   

Abstract

Background: Prothymosin α (ProT), a polypeptide, attenuates inflammation and inhibits transforming growth factor (TGF)-β signaling in pulmonary tissues. We investigated the potential role of ProT in myocardial ischemia-reperfusion (MyoIR) injury using ProT cDNA transfer.
Methods: Serum ProT levels were investigated in cardiogenic shock patients with MyoIR (n = 9). In addition, the myocardium of Sprague-Dawley rats (n = 52) was subjected to 25 min of ischemia followed by an injection of adenoviral vectors (2 × 109 plaque-forming units) carrying ProT or the luciferase gene, 10 min before reperfusion. Echocardiography, serum ProT, and biochemical analyses of organ functions were performed before euthanasia, 14 days after treatment. Immunohistochemistry and immunoblotting of the myocardial tissue were also performed.
Results: Serum ProT levels were transiently elevated in the rats and patients early after MyoIR, which was reduced to baseline levels in control rats and patients. ProT gene transfer persistently mobilized ProT serum levels, reduced dilatation, attenuated fibrotic changes, and preserved the left ventricular ejection fraction after MyoIR. Tissue thrombospondin-1 level was abundant, and matrix metalloproteinase-2, collagen I, and collagen IV levels were decreased in the treatment group. While TGF-β protein level remained stable, ProT transduction mobilized Smad7, which counteracted TGF-β. ProT reduced tissue microRNA-223 expression, inhibited the associated interleukin-1β, and preserved RAS p21 protein activator 1 protein abundance. Conclusions: An increase in transient serum ProT levels could be a protective response in the acute stage of MyoIR. ProT gene transfer further preserved ventricular morphology and function through anti-inflammatory and anti-fibrotic effects in the subacute stage after injury.

Entities:  

Keywords:  Ischemia-reperfusion; Prothymosin α; Transforming growth factor-β

Year:  2022        PMID: 35273440      PMCID: PMC8888327          DOI: 10.6515/ACS.202203_38(2).20211115A

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  32 in total

1.  Rosuvastatin improves vascular function of arteriovenous fistula in a diabetic rat model.

Authors:  Jun-Neng Roan; Shih-Yuan Fang; Shih-Wei Chang; Chih-Hsin Hsu; Chein-Chi Huang; Meng-Hsuan Chiou; Yu-Chuan Tsai; Chen-Fuh Lam
Journal:  J Vasc Surg       Date:  2012-06-22       Impact factor: 4.268

2.  Bridge-to-recovery strategy using extracorporeal membrane oxygenation for critical pulmonary hypertension complicated with cardiogenic shock.

Authors:  Meng-Ta Tsai; Chih-Hsin Hsu; Chwan-Yau Luo; Yu-Ning Hu; Jun-Neng Roan
Journal:  Interact Cardiovasc Thorac Surg       Date:  2015-03-29

3.  Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.

Authors:  Yeong-Chin Jou; Yuh-Shyan Tsai; Hsiao-Yen Hsieh; Syue-Yi Chen; Hsin-Tzu Tsai; Ko-Jung Chen; Shan-Tair Wang; Ai-Li Shiau; Chao-Liang Wu; Tzong-Shin Tzai
Journal:  Urol Oncol       Date:  2012-05-19       Impact factor: 3.498

4.  MicroRNA-223 Regulates Cardiac Fibrosis After Myocardial Infarction by Targeting RASA1.

Authors:  Xiaoxiao Liu; Yifeng Xu; Yunfei Deng; Hongli Li
Journal:  Cell Physiol Biochem       Date:  2018-04-19

5.  Prothymosin alpha protects cardiomyocytes against ischemia-induced apoptosis via preservation of Akt activation.

Authors:  Alessandro Cannavo; Giuseppe Rengo; Daniela Liccardo; Gianluigi Pironti; Maria Cecilia Scimia; Laura Scudiero; Claudio De Lucia; Marco Ferrone; Dario Leosco; Nicola Zambrano; Walter J Koch; Bruno Trimarco; Giovanni Esposito
Journal:  Apoptosis       Date:  2013-10       Impact factor: 4.677

6.  Inhibition of cyclooxygenase-2 modulates phenotypic switching of vascular smooth muscle cells during increased aortic blood flow.

Authors:  Jun-Neng Roan; Yu-Chuan Tsai; I-Wen Chen; Shih-Wei Chang; Chien-Chi Huang; Chen-Fuh Lam
Journal:  Heart Vessels       Date:  2011-05-17       Impact factor: 2.037

7.  Simultaneous thrombolysis and extracorporeal membrane oxygenation for acute massive pulmonary emboli.

Authors:  Ting-Wei Lin; Meng-Ta Tsai; Yu-Ning Hu; Yi-Chen Wang; Jih-Sheng Wen; Hsuan-Yin Wu; Chwan-Yau Luo; Jun-Neng Roan
Journal:  Ann Thorac Surg       Date:  2020-07-29       Impact factor: 4.330

Review 8.  Myocardial ischemia-reperfusion injury: a neglected therapeutic target.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

Review 9.  Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: Mechanisms, incidence and identification of patients at risk.

Authors:  Thomas J Cahill; Rajesh K Kharbanda
Journal:  World J Cardiol       Date:  2017-05-26

Review 10.  TGF-β and WNT signaling pathways in cardiac fibrosis: non-coding RNAs come into focus.

Authors:  Fatemeh Yousefi; Zahra Shabaninejad; Sina Vakili; Maryam Derakhshan; Ahmad Movahedpour; Hamed Dabiri; Younes Ghasemi; Maryam Mahjoubin-Tehran; Azin Nikoozadeh; Amir Savardashtaki; Hamed Mirzaei; Michael R Hamblin
Journal:  Cell Commun Signal       Date:  2020-06-09       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.